Global iPSC-Derived Natural Killer Cells Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global iPSC-Derived Natural Killer Cells market size was valued at US$ 170 million in 2025 and is forecast to a readjusted size of US$ 1106 million by 2032 with a CAGR of 30.3% during review period.
iPSC-Derived Natural Killer (NK) Cells refer to NK-like immune effector cells generated from induced pluripotent stem cells (iPSCs) through sequential processes including hematopoietic differentiation, NK cell maturation, expansion, purification, and quality control. These cells can be applied in cancer immunotherapy, B-cell depletion research for autoimmune diseases, infectious disease modeling, and cell therapy manufacturing process development. Key advantages include a standardized cell source, strong batch-to-batch consistency, and high amenability to multi-gene engineering at the iPSC stage, such as CAR insertion, CD16 enhancement, IL-15 expression, and immune-evasion modifications. These cells also support cryopreserved off-the-shelf production. The product category is currently mainly positioned in research-use products, CDMO process platforms, and clinical-stage therapeutic candidates. The overall gross margin is approximately 60%.
The evolution of cancer immunotherapy from autologous CAR-T toward allogeneic, off-the-shelf, and repeat-dose cell therapies is driving iPSC-derived NK cells to become a key next-generation modality. Their core value lies in enabling scalable production from a single master cell bank, thereby reducing donor variability and manufacturing scheduling constraints. In addition, iPSC-derived NK cells can be combined with monoclonal antibodies, bispecific or multispecific NK cell engagers, CAR constructs, and other immune-modulating strategies, enabling applications across hematologic malignancies, solid tumors, and B-cell?mediated autoimmune diseases.
Competitive dynamics are shifting from basic NK cell generation toward advanced cell engineering design, GMP-scale manufacturing, post-thaw functional activity, and batch consistency control. Leading companies typically introduce multi-gene engineering at the iPSC stage, followed by closed-system suspension culture, automated differentiation processes, and standardized quality control to improve manufacturability. In the near term, commercial value is concentrated in clinical-grade cell banks, process development services, CDMO manufacturing, and clinical trial supply. Long-term success depends on demonstrating durable efficacy, safety, and improved tumor infiltration capability, particularly in solid tumor indications.
North America remains the dominant region for clinical translation and capital investment, while Japan, Australia, and China are advancing rapidly in iPSC cell banking, regulatory exploration, and domestic clinical programs. Key uncertainties include long-term safety, residual undifferentiated iPSC control, immune rejection risk, scalability costs, and regulatory approval pathways. If engineering strategies and manufacturing economics continue to improve, iPSC-derived NK cells are expected to establish a differentiated position within the allogeneic cell therapy landscape.
Report Scope
This report is a detailed and comprehensive analysis for global iPSC-Derived Natural Killer Cells market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global iPSC-Derived Natural Killer Cells market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
iPSC-Derived Natural Killer Cells market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe iPSC-Derived Natural Killer Cells product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of iPSC-Derived Natural Killer Cells, with price, sales quantity, revenue, and global market share of iPSC-Derived Natural Killer Cells from 2021 to 2026.
Chapter 3, the iPSC-Derived Natural Killer Cells competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the iPSC-Derived Natural Killer Cells breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and iPSC-Derived Natural Killer Cells market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of iPSC-Derived Natural Killer Cells.
Chapter 14 and 15, to describe iPSC-Derived Natural Killer Cells sales channel, distributors, customers, research findings and conclusion.
iPSC-Derived Natural Killer (NK) Cells refer to NK-like immune effector cells generated from induced pluripotent stem cells (iPSCs) through sequential processes including hematopoietic differentiation, NK cell maturation, expansion, purification, and quality control. These cells can be applied in cancer immunotherapy, B-cell depletion research for autoimmune diseases, infectious disease modeling, and cell therapy manufacturing process development. Key advantages include a standardized cell source, strong batch-to-batch consistency, and high amenability to multi-gene engineering at the iPSC stage, such as CAR insertion, CD16 enhancement, IL-15 expression, and immune-evasion modifications. These cells also support cryopreserved off-the-shelf production. The product category is currently mainly positioned in research-use products, CDMO process platforms, and clinical-stage therapeutic candidates. The overall gross margin is approximately 60%.
The evolution of cancer immunotherapy from autologous CAR-T toward allogeneic, off-the-shelf, and repeat-dose cell therapies is driving iPSC-derived NK cells to become a key next-generation modality. Their core value lies in enabling scalable production from a single master cell bank, thereby reducing donor variability and manufacturing scheduling constraints. In addition, iPSC-derived NK cells can be combined with monoclonal antibodies, bispecific or multispecific NK cell engagers, CAR constructs, and other immune-modulating strategies, enabling applications across hematologic malignancies, solid tumors, and B-cell?mediated autoimmune diseases.
Competitive dynamics are shifting from basic NK cell generation toward advanced cell engineering design, GMP-scale manufacturing, post-thaw functional activity, and batch consistency control. Leading companies typically introduce multi-gene engineering at the iPSC stage, followed by closed-system suspension culture, automated differentiation processes, and standardized quality control to improve manufacturability. In the near term, commercial value is concentrated in clinical-grade cell banks, process development services, CDMO manufacturing, and clinical trial supply. Long-term success depends on demonstrating durable efficacy, safety, and improved tumor infiltration capability, particularly in solid tumor indications.
North America remains the dominant region for clinical translation and capital investment, while Japan, Australia, and China are advancing rapidly in iPSC cell banking, regulatory exploration, and domestic clinical programs. Key uncertainties include long-term safety, residual undifferentiated iPSC control, immune rejection risk, scalability costs, and regulatory approval pathways. If engineering strategies and manufacturing economics continue to improve, iPSC-derived NK cells are expected to establish a differentiated position within the allogeneic cell therapy landscape.
Report Scope
This report is a detailed and comprehensive analysis for global iPSC-Derived Natural Killer Cells market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global iPSC-Derived Natural Killer Cells market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global iPSC-Derived Natural Killer Cells market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for iPSC-Derived Natural Killer Cells
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
iPSC-Derived Natural Killer Cells market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Non-Engineered iPSC-Derived NK Cells
- CAR-Engineered iPSC-Derived NK Cells
- CD16-Enhanced iPSC-Derived NK Cells
- Immune-Evasive iPSC-Derived NK Cells
- Multi-Functional iPSC-Derived NK Cells
- Healthy Donor iPSC Line
- GMP Master iPSC Bank
- Gene-Edited Universal iPSC Line
- HLA-Matched iPSC Bank
- Patient-Specific iPSC Line
- Hematologic Malignancies
- Solid Tumors
- Autoimmune Diseases
- Infectious Diseases
- Inflammation and Tissue Repair
- Other Research Uses
- Research-Use Cell Product
- Preclinical Candidate
- Clinical-Grade Drug Product
- CDMO Manufacturing Service
- Cell Bank and Starting Material
- Cancer Immunotherapy
- Autoimmune Disease Therapy
- Infectious Disease Research
- Drug Screening and Mechanism Studies
- Cell Therapy Process Development
- Other Applications
- Fate Therapeutics
- Century Therapeutics
- Cartherics
- Nuwacell Biotech
- HebeCell
- Healios
- Cytovia Therapeutics
- Shoreline Biosciences
- Applied StemCell
- Cellistic
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe iPSC-Derived Natural Killer Cells product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of iPSC-Derived Natural Killer Cells, with price, sales quantity, revenue, and global market share of iPSC-Derived Natural Killer Cells from 2021 to 2026.
Chapter 3, the iPSC-Derived Natural Killer Cells competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the iPSC-Derived Natural Killer Cells breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and iPSC-Derived Natural Killer Cells market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of iPSC-Derived Natural Killer Cells.
Chapter 14 and 15, to describe iPSC-Derived Natural Killer Cells sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Non-Engineered iPSC-Derived NK Cells
1.3.3 CAR-Engineered iPSC-Derived NK Cells
1.3.4 CD16-Enhanced iPSC-Derived NK Cells
1.3.5 Immune-Evasive iPSC-Derived NK Cells
1.3.6 Multi-Functional iPSC-Derived NK Cells
1.4 Market Analysis by Cell Source Strategy
1.4.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Cell Source Strategy: 2021 Versus 2025 Versus 2032
1.4.2 Healthy Donor iPSC Line
1.4.3 GMP Master iPSC Bank
1.4.4 Gene-Edited Universal iPSC Line
1.4.5 HLA-Matched iPSC Bank
1.4.6 Patient-Specific iPSC Line
1.5 Market Analysis by Therapeutic Indication
1.5.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Therapeutic Indication: 2021 Versus 2025 Versus 2032
1.5.2 Hematologic Malignancies
1.5.3 Solid Tumors
1.5.4 Autoimmune Diseases
1.5.5 Infectious Diseases
1.5.6 Inflammation and Tissue Repair
1.5.7 Other Research Uses
1.6 Market Analysis by Development and Delivery Format
1.6.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Development and Delivery Format: 2021 Versus 2025 Versus 2032
1.6.2 Research-Use Cell Product
1.6.3 Preclinical Candidate
1.6.4 Clinical-Grade Drug Product
1.6.5 CDMO Manufacturing Service
1.6.6 Cell Bank and Starting Material
1.7 Market Analysis by Application
1.7.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Cancer Immunotherapy
1.7.3 Autoimmune Disease Therapy
1.7.4 Infectious Disease Research
1.7.5 Drug Screening and Mechanism Studies
1.7.6 Cell Therapy Process Development
1.7.7 Other Applications
1.8 Global iPSC-Derived Natural Killer Cells Market Size & Forecast
1.8.1 Global iPSC-Derived Natural Killer Cells Consumption Value (2021 & 2025 & 2032)
1.8.2 Global iPSC-Derived Natural Killer Cells Sales Quantity (2021-2032)
1.8.3 Global iPSC-Derived Natural Killer Cells Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Fate Therapeutics
2.1.1 Fate Therapeutics Details
2.1.2 Fate Therapeutics Major Business
2.1.3 Fate Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.1.4 Fate Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Fate Therapeutics Recent Developments/Updates
2.2 Century Therapeutics
2.2.1 Century Therapeutics Details
2.2.2 Century Therapeutics Major Business
2.2.3 Century Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.2.4 Century Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Century Therapeutics Recent Developments/Updates
2.3 Cartherics
2.3.1 Cartherics Details
2.3.2 Cartherics Major Business
2.3.3 Cartherics iPSC-Derived Natural Killer Cells Product and Services
2.3.4 Cartherics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Cartherics Recent Developments/Updates
2.4 Nuwacell Biotech
2.4.1 Nuwacell Biotech Details
2.4.2 Nuwacell Biotech Major Business
2.4.3 Nuwacell Biotech iPSC-Derived Natural Killer Cells Product and Services
2.4.4 Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Nuwacell Biotech Recent Developments/Updates
2.5 HebeCell
2.5.1 HebeCell Details
2.5.2 HebeCell Major Business
2.5.3 HebeCell iPSC-Derived Natural Killer Cells Product and Services
2.5.4 HebeCell iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 HebeCell Recent Developments/Updates
2.6 Healios
2.6.1 Healios Details
2.6.2 Healios Major Business
2.6.3 Healios iPSC-Derived Natural Killer Cells Product and Services
2.6.4 Healios iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Healios Recent Developments/Updates
2.7 Cytovia Therapeutics
2.7.1 Cytovia Therapeutics Details
2.7.2 Cytovia Therapeutics Major Business
2.7.3 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.7.4 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Cytovia Therapeutics Recent Developments/Updates
2.8 Shoreline Biosciences
2.8.1 Shoreline Biosciences Details
2.8.2 Shoreline Biosciences Major Business
2.8.3 Shoreline Biosciences iPSC-Derived Natural Killer Cells Product and Services
2.8.4 Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Shoreline Biosciences Recent Developments/Updates
2.9 Applied StemCell
2.9.1 Applied StemCell Details
2.9.2 Applied StemCell Major Business
2.9.3 Applied StemCell iPSC-Derived Natural Killer Cells Product and Services
2.9.4 Applied StemCell iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Applied StemCell Recent Developments/Updates
2.10 Cellistic
2.10.1 Cellistic Details
2.10.2 Cellistic Major Business
2.10.3 Cellistic iPSC-Derived Natural Killer Cells Product and Services
2.10.4 Cellistic iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Cellistic Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: IPSC-DERIVED NATURAL KILLER CELLS BY MANUFACTURER
3.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Manufacturer (2021-2026)
3.2 Global iPSC-Derived Natural Killer Cells Revenue by Manufacturer (2021-2026)
3.3 Global iPSC-Derived Natural Killer Cells Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of iPSC-Derived Natural Killer Cells by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 iPSC-Derived Natural Killer Cells Manufacturer Market Share in 2025
3.4.3 Top 6 iPSC-Derived Natural Killer Cells Manufacturer Market Share in 2025
3.5 iPSC-Derived Natural Killer Cells Market: Overall Company Footprint Analysis
3.5.1 iPSC-Derived Natural Killer Cells Market: Region Footprint
3.5.2 iPSC-Derived Natural Killer Cells Market: Company Product Type Footprint
3.5.3 iPSC-Derived Natural Killer Cells Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global iPSC-Derived Natural Killer Cells Market Size by Region
4.1.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2032)
4.1.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2032)
4.1.3 Global iPSC-Derived Natural Killer Cells Average Price by Region (2021-2032)
4.2 North America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.3 Europe iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.4 Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.5 South America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.6 Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
5.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2021-2032)
5.3 Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
6.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2021-2032)
6.3 Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
7.2 North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
7.3 North America iPSC-Derived Natural Killer Cells Market Size by Country
7.3.1 North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
7.3.2 North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
8.2 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
8.3 Europe iPSC-Derived Natural Killer Cells Market Size by Country
8.3.1 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
8.3.2 Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific iPSC-Derived Natural Killer Cells Market Size by Region
9.3.1 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
10.2 South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
10.3 South America iPSC-Derived Natural Killer Cells Market Size by Country
10.3.1 South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
10.3.2 South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa iPSC-Derived Natural Killer Cells Market Size by Country
11.3.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 iPSC-Derived Natural Killer Cells Market Drivers
12.2 iPSC-Derived Natural Killer Cells Market Restraints
12.3 iPSC-Derived Natural Killer Cells Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of iPSC-Derived Natural Killer Cells and Key Manufacturers
13.2 Manufacturing Costs Percentage of iPSC-Derived Natural Killer Cells
13.3 iPSC-Derived Natural Killer Cells Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 iPSC-Derived Natural Killer Cells Typical Distributors
14.3 iPSC-Derived Natural Killer Cells Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 Non-Engineered iPSC-Derived NK Cells
1.3.3 CAR-Engineered iPSC-Derived NK Cells
1.3.4 CD16-Enhanced iPSC-Derived NK Cells
1.3.5 Immune-Evasive iPSC-Derived NK Cells
1.3.6 Multi-Functional iPSC-Derived NK Cells
1.4 Market Analysis by Cell Source Strategy
1.4.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Cell Source Strategy: 2021 Versus 2025 Versus 2032
1.4.2 Healthy Donor iPSC Line
1.4.3 GMP Master iPSC Bank
1.4.4 Gene-Edited Universal iPSC Line
1.4.5 HLA-Matched iPSC Bank
1.4.6 Patient-Specific iPSC Line
1.5 Market Analysis by Therapeutic Indication
1.5.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Therapeutic Indication: 2021 Versus 2025 Versus 2032
1.5.2 Hematologic Malignancies
1.5.3 Solid Tumors
1.5.4 Autoimmune Diseases
1.5.5 Infectious Diseases
1.5.6 Inflammation and Tissue Repair
1.5.7 Other Research Uses
1.6 Market Analysis by Development and Delivery Format
1.6.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Development and Delivery Format: 2021 Versus 2025 Versus 2032
1.6.2 Research-Use Cell Product
1.6.3 Preclinical Candidate
1.6.4 Clinical-Grade Drug Product
1.6.5 CDMO Manufacturing Service
1.6.6 Cell Bank and Starting Material
1.7 Market Analysis by Application
1.7.1 Overview: Global iPSC-Derived Natural Killer Cells Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.7.2 Cancer Immunotherapy
1.7.3 Autoimmune Disease Therapy
1.7.4 Infectious Disease Research
1.7.5 Drug Screening and Mechanism Studies
1.7.6 Cell Therapy Process Development
1.7.7 Other Applications
1.8 Global iPSC-Derived Natural Killer Cells Market Size & Forecast
1.8.1 Global iPSC-Derived Natural Killer Cells Consumption Value (2021 & 2025 & 2032)
1.8.2 Global iPSC-Derived Natural Killer Cells Sales Quantity (2021-2032)
1.8.3 Global iPSC-Derived Natural Killer Cells Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Fate Therapeutics
2.1.1 Fate Therapeutics Details
2.1.2 Fate Therapeutics Major Business
2.1.3 Fate Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.1.4 Fate Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Fate Therapeutics Recent Developments/Updates
2.2 Century Therapeutics
2.2.1 Century Therapeutics Details
2.2.2 Century Therapeutics Major Business
2.2.3 Century Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.2.4 Century Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Century Therapeutics Recent Developments/Updates
2.3 Cartherics
2.3.1 Cartherics Details
2.3.2 Cartherics Major Business
2.3.3 Cartherics iPSC-Derived Natural Killer Cells Product and Services
2.3.4 Cartherics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Cartherics Recent Developments/Updates
2.4 Nuwacell Biotech
2.4.1 Nuwacell Biotech Details
2.4.2 Nuwacell Biotech Major Business
2.4.3 Nuwacell Biotech iPSC-Derived Natural Killer Cells Product and Services
2.4.4 Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Nuwacell Biotech Recent Developments/Updates
2.5 HebeCell
2.5.1 HebeCell Details
2.5.2 HebeCell Major Business
2.5.3 HebeCell iPSC-Derived Natural Killer Cells Product and Services
2.5.4 HebeCell iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 HebeCell Recent Developments/Updates
2.6 Healios
2.6.1 Healios Details
2.6.2 Healios Major Business
2.6.3 Healios iPSC-Derived Natural Killer Cells Product and Services
2.6.4 Healios iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Healios Recent Developments/Updates
2.7 Cytovia Therapeutics
2.7.1 Cytovia Therapeutics Details
2.7.2 Cytovia Therapeutics Major Business
2.7.3 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product and Services
2.7.4 Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Cytovia Therapeutics Recent Developments/Updates
2.8 Shoreline Biosciences
2.8.1 Shoreline Biosciences Details
2.8.2 Shoreline Biosciences Major Business
2.8.3 Shoreline Biosciences iPSC-Derived Natural Killer Cells Product and Services
2.8.4 Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Shoreline Biosciences Recent Developments/Updates
2.9 Applied StemCell
2.9.1 Applied StemCell Details
2.9.2 Applied StemCell Major Business
2.9.3 Applied StemCell iPSC-Derived Natural Killer Cells Product and Services
2.9.4 Applied StemCell iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Applied StemCell Recent Developments/Updates
2.10 Cellistic
2.10.1 Cellistic Details
2.10.2 Cellistic Major Business
2.10.3 Cellistic iPSC-Derived Natural Killer Cells Product and Services
2.10.4 Cellistic iPSC-Derived Natural Killer Cells Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Cellistic Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: IPSC-DERIVED NATURAL KILLER CELLS BY MANUFACTURER
3.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Manufacturer (2021-2026)
3.2 Global iPSC-Derived Natural Killer Cells Revenue by Manufacturer (2021-2026)
3.3 Global iPSC-Derived Natural Killer Cells Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of iPSC-Derived Natural Killer Cells by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 iPSC-Derived Natural Killer Cells Manufacturer Market Share in 2025
3.4.3 Top 6 iPSC-Derived Natural Killer Cells Manufacturer Market Share in 2025
3.5 iPSC-Derived Natural Killer Cells Market: Overall Company Footprint Analysis
3.5.1 iPSC-Derived Natural Killer Cells Market: Region Footprint
3.5.2 iPSC-Derived Natural Killer Cells Market: Company Product Type Footprint
3.5.3 iPSC-Derived Natural Killer Cells Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global iPSC-Derived Natural Killer Cells Market Size by Region
4.1.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2032)
4.1.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2032)
4.1.3 Global iPSC-Derived Natural Killer Cells Average Price by Region (2021-2032)
4.2 North America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.3 Europe iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.4 Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.5 South America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
4.6 Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
5.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2021-2032)
5.3 Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
6.2 Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2021-2032)
6.3 Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
7.2 North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
7.3 North America iPSC-Derived Natural Killer Cells Market Size by Country
7.3.1 North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
7.3.2 North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
8.2 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
8.3 Europe iPSC-Derived Natural Killer Cells Market Size by Country
8.3.1 Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
8.3.2 Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific iPSC-Derived Natural Killer Cells Market Size by Region
9.3.1 Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
10.2 South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
10.3 South America iPSC-Derived Natural Killer Cells Market Size by Country
10.3.1 South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
10.3.2 South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa iPSC-Derived Natural Killer Cells Market Size by Country
11.3.1 Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 iPSC-Derived Natural Killer Cells Market Drivers
12.2 iPSC-Derived Natural Killer Cells Market Restraints
12.3 iPSC-Derived Natural Killer Cells Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of iPSC-Derived Natural Killer Cells and Key Manufacturers
13.2 Manufacturing Costs Percentage of iPSC-Derived Natural Killer Cells
13.3 iPSC-Derived Natural Killer Cells Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 iPSC-Derived Natural Killer Cells Typical Distributors
14.3 iPSC-Derived Natural Killer Cells Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global iPSC-Derived Natural Killer Cells Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global iPSC-Derived Natural Killer Cells Consumption Value by Cell Source Strategy, (USD Million), 2021 & 2025 & 2032
Table 3. Global iPSC-Derived Natural Killer Cells Consumption Value by Therapeutic Indication, (USD Million), 2021 & 2025 & 2032
Table 4. Global iPSC-Derived Natural Killer Cells Consumption Value by Development and Delivery Format, (USD Million), 2021 & 2025 & 2032
Table 5. Global iPSC-Derived Natural Killer Cells Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 7. Fate Therapeutics Major Business
Table 8. Fate Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 9. Fate Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Fate Therapeutics Recent Developments/Updates
Table 11. Century Therapeutics Basic Information, Manufacturing Base and Competitors
Table 12. Century Therapeutics Major Business
Table 13. Century Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 14. Century Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Century Therapeutics Recent Developments/Updates
Table 16. Cartherics Basic Information, Manufacturing Base and Competitors
Table 17. Cartherics Major Business
Table 18. Cartherics iPSC-Derived Natural Killer Cells Product and Services
Table 19. Cartherics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Cartherics Recent Developments/Updates
Table 21. Nuwacell Biotech Basic Information, Manufacturing Base and Competitors
Table 22. Nuwacell Biotech Major Business
Table 23. Nuwacell Biotech iPSC-Derived Natural Killer Cells Product and Services
Table 24. Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Nuwacell Biotech Recent Developments/Updates
Table 26. HebeCell Basic Information, Manufacturing Base and Competitors
Table 27. HebeCell Major Business
Table 28. HebeCell iPSC-Derived Natural Killer Cells Product and Services
Table 29. HebeCell iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. HebeCell Recent Developments/Updates
Table 31. Healios Basic Information, Manufacturing Base and Competitors
Table 32. Healios Major Business
Table 33. Healios iPSC-Derived Natural Killer Cells Product and Services
Table 34. Healios iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Healios Recent Developments/Updates
Table 36. Cytovia Therapeutics Basic Information, Manufacturing Base and Competitors
Table 37. Cytovia Therapeutics Major Business
Table 38. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 39. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Cytovia Therapeutics Recent Developments/Updates
Table 41. Shoreline Biosciences Basic Information, Manufacturing Base and Competitors
Table 42. Shoreline Biosciences Major Business
Table 43. Shoreline Biosciences iPSC-Derived Natural Killer Cells Product and Services
Table 44. Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Shoreline Biosciences Recent Developments/Updates
Table 46. Applied StemCell Basic Information, Manufacturing Base and Competitors
Table 47. Applied StemCell Major Business
Table 48. Applied StemCell iPSC-Derived Natural Killer Cells Product and Services
Table 49. Applied StemCell iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Applied StemCell Recent Developments/Updates
Table 51. Cellistic Basic Information, Manufacturing Base and Competitors
Table 52. Cellistic Major Business
Table 53. Cellistic iPSC-Derived Natural Killer Cells Product and Services
Table 54. Cellistic iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Cellistic Recent Developments/Updates
Table 56. Global iPSC-Derived Natural Killer Cells Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 57. Global iPSC-Derived Natural Killer Cells Revenue by Manufacturer (2021-2026) & (USD Million)
Table 58. Global iPSC-Derived Natural Killer Cells Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 59. Market Position of Manufacturers in iPSC-Derived Natural Killer Cells, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 60. Head Office and iPSC-Derived Natural Killer Cells Production Site of Key Manufacturer
Table 61. iPSC-Derived Natural Killer Cells Market: Company Product Type Footprint
Table 62. iPSC-Derived Natural Killer Cells Market: Company Product Application Footprint
Table 63. iPSC-Derived Natural Killer Cells New Market Entrants and Barriers to Market Entry
Table 64. iPSC-Derived Natural Killer Cells Mergers, Acquisition, Agreements, and Collaborations
Table 65. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 66. Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2026) & (K Dose)
Table 67. Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2027-2032) & (K Dose)
Table 68. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2026) & (USD Million)
Table 69. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2027-2032) & (USD Million)
Table 70. Global iPSC-Derived Natural Killer Cells Average Price by Region (2021-2026) & (US$/Dose)
Table 71. Global iPSC-Derived Natural Killer Cells Average Price by Region (2027-2032) & (US$/Dose)
Table 72. Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 73. Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 74. Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2021-2026) & (USD Million)
Table 75. Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2027-2032) & (USD Million)
Table 76. Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2026) & (US$/Dose)
Table 77. Global iPSC-Derived Natural Killer Cells Average Price by Type (2027-2032) & (US$/Dose)
Table 78. Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 79. Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 80. Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2021-2026) & (USD Million)
Table 81. Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2027-2032) & (USD Million)
Table 82. Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2026) & (US$/Dose)
Table 83. Global iPSC-Derived Natural Killer Cells Average Price by Application (2027-2032) & (US$/Dose)
Table 84. North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 85. North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 86. North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 87. North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 88. North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 89. North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 90. North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 91. North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 93. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 94. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 95. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 96. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 97. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 98. Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 99. Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 100. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 101. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 102. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 103. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 104. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2026) & (K Dose)
Table 105. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2027-2032) & (K Dose)
Table 106. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2026) & (USD Million)
Table 107. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2027-2032) & (USD Million)
Table 108. South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 109. South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 110. South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 111. South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 112. South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 113. South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 114. South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 115. South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 117. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 118. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 119. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 120. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 121. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 122. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 123. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 124. iPSC-Derived Natural Killer Cells Raw Material
Table 125. Key Manufacturers of iPSC-Derived Natural Killer Cells Raw Materials
Table 126. iPSC-Derived Natural Killer Cells Typical Distributors
Table 127. iPSC-Derived Natural Killer Cells Typical Customers
Table 1. Global iPSC-Derived Natural Killer Cells Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global iPSC-Derived Natural Killer Cells Consumption Value by Cell Source Strategy, (USD Million), 2021 & 2025 & 2032
Table 3. Global iPSC-Derived Natural Killer Cells Consumption Value by Therapeutic Indication, (USD Million), 2021 & 2025 & 2032
Table 4. Global iPSC-Derived Natural Killer Cells Consumption Value by Development and Delivery Format, (USD Million), 2021 & 2025 & 2032
Table 5. Global iPSC-Derived Natural Killer Cells Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 6. Fate Therapeutics Basic Information, Manufacturing Base and Competitors
Table 7. Fate Therapeutics Major Business
Table 8. Fate Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 9. Fate Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 10. Fate Therapeutics Recent Developments/Updates
Table 11. Century Therapeutics Basic Information, Manufacturing Base and Competitors
Table 12. Century Therapeutics Major Business
Table 13. Century Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 14. Century Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 15. Century Therapeutics Recent Developments/Updates
Table 16. Cartherics Basic Information, Manufacturing Base and Competitors
Table 17. Cartherics Major Business
Table 18. Cartherics iPSC-Derived Natural Killer Cells Product and Services
Table 19. Cartherics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 20. Cartherics Recent Developments/Updates
Table 21. Nuwacell Biotech Basic Information, Manufacturing Base and Competitors
Table 22. Nuwacell Biotech Major Business
Table 23. Nuwacell Biotech iPSC-Derived Natural Killer Cells Product and Services
Table 24. Nuwacell Biotech iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Nuwacell Biotech Recent Developments/Updates
Table 26. HebeCell Basic Information, Manufacturing Base and Competitors
Table 27. HebeCell Major Business
Table 28. HebeCell iPSC-Derived Natural Killer Cells Product and Services
Table 29. HebeCell iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. HebeCell Recent Developments/Updates
Table 31. Healios Basic Information, Manufacturing Base and Competitors
Table 32. Healios Major Business
Table 33. Healios iPSC-Derived Natural Killer Cells Product and Services
Table 34. Healios iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Healios Recent Developments/Updates
Table 36. Cytovia Therapeutics Basic Information, Manufacturing Base and Competitors
Table 37. Cytovia Therapeutics Major Business
Table 38. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Product and Services
Table 39. Cytovia Therapeutics iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Cytovia Therapeutics Recent Developments/Updates
Table 41. Shoreline Biosciences Basic Information, Manufacturing Base and Competitors
Table 42. Shoreline Biosciences Major Business
Table 43. Shoreline Biosciences iPSC-Derived Natural Killer Cells Product and Services
Table 44. Shoreline Biosciences iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Shoreline Biosciences Recent Developments/Updates
Table 46. Applied StemCell Basic Information, Manufacturing Base and Competitors
Table 47. Applied StemCell Major Business
Table 48. Applied StemCell iPSC-Derived Natural Killer Cells Product and Services
Table 49. Applied StemCell iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Applied StemCell Recent Developments/Updates
Table 51. Cellistic Basic Information, Manufacturing Base and Competitors
Table 52. Cellistic Major Business
Table 53. Cellistic iPSC-Derived Natural Killer Cells Product and Services
Table 54. Cellistic iPSC-Derived Natural Killer Cells Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Cellistic Recent Developments/Updates
Table 56. Global iPSC-Derived Natural Killer Cells Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 57. Global iPSC-Derived Natural Killer Cells Revenue by Manufacturer (2021-2026) & (USD Million)
Table 58. Global iPSC-Derived Natural Killer Cells Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 59. Market Position of Manufacturers in iPSC-Derived Natural Killer Cells, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 60. Head Office and iPSC-Derived Natural Killer Cells Production Site of Key Manufacturer
Table 61. iPSC-Derived Natural Killer Cells Market: Company Product Type Footprint
Table 62. iPSC-Derived Natural Killer Cells Market: Company Product Application Footprint
Table 63. iPSC-Derived Natural Killer Cells New Market Entrants and Barriers to Market Entry
Table 64. iPSC-Derived Natural Killer Cells Mergers, Acquisition, Agreements, and Collaborations
Table 65. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 66. Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2026) & (K Dose)
Table 67. Global iPSC-Derived Natural Killer Cells Sales Quantity by Region (2027-2032) & (K Dose)
Table 68. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2026) & (USD Million)
Table 69. Global iPSC-Derived Natural Killer Cells Consumption Value by Region (2027-2032) & (USD Million)
Table 70. Global iPSC-Derived Natural Killer Cells Average Price by Region (2021-2026) & (US$/Dose)
Table 71. Global iPSC-Derived Natural Killer Cells Average Price by Region (2027-2032) & (US$/Dose)
Table 72. Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 73. Global iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 74. Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2021-2026) & (USD Million)
Table 75. Global iPSC-Derived Natural Killer Cells Consumption Value by Type (2027-2032) & (USD Million)
Table 76. Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2026) & (US$/Dose)
Table 77. Global iPSC-Derived Natural Killer Cells Average Price by Type (2027-2032) & (US$/Dose)
Table 78. Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 79. Global iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 80. Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2021-2026) & (USD Million)
Table 81. Global iPSC-Derived Natural Killer Cells Consumption Value by Application (2027-2032) & (USD Million)
Table 82. Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2026) & (US$/Dose)
Table 83. Global iPSC-Derived Natural Killer Cells Average Price by Application (2027-2032) & (US$/Dose)
Table 84. North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 85. North America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 86. North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 87. North America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 88. North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 89. North America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 90. North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 91. North America iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 92. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 93. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 94. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 95. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 96. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 97. Europe iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 98. Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 99. Europe iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 100. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 101. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 102. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 103. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 104. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2021-2026) & (K Dose)
Table 105. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity by Region (2027-2032) & (K Dose)
Table 106. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2021-2026) & (USD Million)
Table 107. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value by Region (2027-2032) & (USD Million)
Table 108. South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 109. South America iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 110. South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 111. South America iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 112. South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 113. South America iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 114. South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 115. South America iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 116. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2021-2026) & (K Dose)
Table 117. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Type (2027-2032) & (K Dose)
Table 118. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2021-2026) & (K Dose)
Table 119. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Application (2027-2032) & (K Dose)
Table 120. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2021-2026) & (K Dose)
Table 121. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity by Country (2027-2032) & (K Dose)
Table 122. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2021-2026) & (USD Million)
Table 123. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value by Country (2027-2032) & (USD Million)
Table 124. iPSC-Derived Natural Killer Cells Raw Material
Table 125. Key Manufacturers of iPSC-Derived Natural Killer Cells Raw Materials
Table 126. iPSC-Derived Natural Killer Cells Typical Distributors
Table 127. iPSC-Derived Natural Killer Cells Typical Customers
LIST OF FIGURES
Figure 1. iPSC-Derived Natural Killer Cells Picture
Figure 2. Global iPSC-Derived Natural Killer Cells Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type in 2025
Figure 4. Non-Engineered iPSC-Derived NK Cells Examples
Figure 5. CAR-Engineered iPSC-Derived NK Cells Examples
Figure 6. CD16-Enhanced iPSC-Derived NK Cells Examples
Figure 7. Immune-Evasive iPSC-Derived NK Cells Examples
Figure 8. Multi-Functional iPSC-Derived NK Cells Examples
Figure 9. Global iPSC-Derived Natural Killer Cells Revenue by Cell Source Strategy, (USD Million), 2021 & 2025 & 2032
Figure 10. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy in 2025
Figure 11. Healthy Donor iPSC Line Examples
Figure 12. GMP Master iPSC Bank Examples
Figure 13. Gene-Edited Universal iPSC Line Examples
Figure 14. HLA-Matched iPSC Bank Examples
Figure 15. Patient-Specific iPSC Line Examples
Figure 16. Global iPSC-Derived Natural Killer Cells Revenue by Therapeutic Indication, (USD Million), 2021 & 2025 & 2032
Figure 17. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication in 2025
Figure 18. Hematologic Malignancies Examples
Figure 19. Solid Tumors Examples
Figure 20. Autoimmune Diseases Examples
Figure 21. Infectious Diseases Examples
Figure 22. Inflammation and Tissue Repair Examples
Figure 23. Other Research Uses Examples
Figure 24. Global iPSC-Derived Natural Killer Cells Revenue by Development and Delivery Format, (USD Million), 2021 & 2025 & 2032
Figure 25. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format in 2025
Figure 26. Research-Use Cell Product Examples
Figure 27. Preclinical Candidate Examples
Figure 28. Clinical-Grade Drug Product Examples
Figure 29. CDMO Manufacturing Service Examples
Figure 30. Cell Bank and Starting Material Examples
Figure 31. Global iPSC-Derived Natural Killer Cells Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application in 2025
Figure 33. Cancer Immunotherapy Examples
Figure 34. Autoimmune Disease Therapy Examples
Figure 35. Infectious Disease Research Examples
Figure 36. Drug Screening and Mechanism Studies Examples
Figure 37. Cell Therapy Process Development Examples
Figure 38. Other Applications Examples
Figure 39. Global iPSC-Derived Natural Killer Cells Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 40. Global iPSC-Derived Natural Killer Cells Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 41. Global iPSC-Derived Natural Killer Cells Sales Quantity (2021-2032) & (K Dose)
Figure 42. Global iPSC-Derived Natural Killer Cells Price (2021-2032) & (US$/Dose)
Figure 43. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Manufacturer in 2025
Figure 44. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Manufacturer in 2025
Figure 45. Producer Shipments of iPSC-Derived Natural Killer Cells by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 46. Top 3 iPSC-Derived Natural Killer Cells Manufacturer (Revenue) Market Share in 2025
Figure 47. Top 6 iPSC-Derived Natural Killer Cells Manufacturer (Revenue) Market Share in 2025
Figure 48. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Region (2021-2032)
Figure 49. Global iPSC-Derived Natural Killer Cells Consumption Value Market Share by Region (2021-2032)
Figure 50. North America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 52. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 53. South America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 54. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 55. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 56. Global iPSC-Derived Natural Killer Cells Consumption Value Market Share by Type (2021-2032)
Figure 57. Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2032) & (US$/Dose)
Figure 58. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 59. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application (2021-2032)
Figure 60. Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2032) & (US$/Dose)
Figure 61. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 62. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 63. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 64. North America iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 65. United States iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 66. Canada iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 67. Mexico iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 68. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 69. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 70. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 71. Europe iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 72. Germany iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 73. France iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 74. United Kingdom iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 75. Russia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 76. Italy iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 77. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 78. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 79. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Region (2021-2032)
Figure 80. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value Market Share by Region (2021-2032)
Figure 81. China iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 82. Japan iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 83. South Korea iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 84. India iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 85. Southeast Asia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 86. Australia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 87. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 88. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 89. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 90. South America iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 91. Brazil iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 92. Argentina iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 93. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 94. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 95. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 96. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 97. Turkey iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 98. Egypt iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 99. Saudi Arabia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 100. South Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 101. iPSC-Derived Natural Killer Cells Market Drivers
Figure 102. iPSC-Derived Natural Killer Cells Market Restraints
Figure 103. iPSC-Derived Natural Killer Cells Market Trends
Figure 104. Porters Five Forces Analysis
Figure 105. Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells in 2025
Figure 106. Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
Figure 107. iPSC-Derived Natural Killer Cells Industrial Chain
Figure 108. Sales Channel: Direct to End-User vs Distributors
Figure 109. Direct Channel Pros & Cons
Figure 110. Indirect Channel Pros & Cons
Figure 111. Methodology
Figure 112. Research Process and Data Source
Figure 1. iPSC-Derived Natural Killer Cells Picture
Figure 2. Global iPSC-Derived Natural Killer Cells Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Type in 2025
Figure 4. Non-Engineered iPSC-Derived NK Cells Examples
Figure 5. CAR-Engineered iPSC-Derived NK Cells Examples
Figure 6. CD16-Enhanced iPSC-Derived NK Cells Examples
Figure 7. Immune-Evasive iPSC-Derived NK Cells Examples
Figure 8. Multi-Functional iPSC-Derived NK Cells Examples
Figure 9. Global iPSC-Derived Natural Killer Cells Revenue by Cell Source Strategy, (USD Million), 2021 & 2025 & 2032
Figure 10. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Cell Source Strategy in 2025
Figure 11. Healthy Donor iPSC Line Examples
Figure 12. GMP Master iPSC Bank Examples
Figure 13. Gene-Edited Universal iPSC Line Examples
Figure 14. HLA-Matched iPSC Bank Examples
Figure 15. Patient-Specific iPSC Line Examples
Figure 16. Global iPSC-Derived Natural Killer Cells Revenue by Therapeutic Indication, (USD Million), 2021 & 2025 & 2032
Figure 17. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Therapeutic Indication in 2025
Figure 18. Hematologic Malignancies Examples
Figure 19. Solid Tumors Examples
Figure 20. Autoimmune Diseases Examples
Figure 21. Infectious Diseases Examples
Figure 22. Inflammation and Tissue Repair Examples
Figure 23. Other Research Uses Examples
Figure 24. Global iPSC-Derived Natural Killer Cells Revenue by Development and Delivery Format, (USD Million), 2021 & 2025 & 2032
Figure 25. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Development and Delivery Format in 2025
Figure 26. Research-Use Cell Product Examples
Figure 27. Preclinical Candidate Examples
Figure 28. Clinical-Grade Drug Product Examples
Figure 29. CDMO Manufacturing Service Examples
Figure 30. Cell Bank and Starting Material Examples
Figure 31. Global iPSC-Derived Natural Killer Cells Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 32. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application in 2025
Figure 33. Cancer Immunotherapy Examples
Figure 34. Autoimmune Disease Therapy Examples
Figure 35. Infectious Disease Research Examples
Figure 36. Drug Screening and Mechanism Studies Examples
Figure 37. Cell Therapy Process Development Examples
Figure 38. Other Applications Examples
Figure 39. Global iPSC-Derived Natural Killer Cells Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 40. Global iPSC-Derived Natural Killer Cells Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 41. Global iPSC-Derived Natural Killer Cells Sales Quantity (2021-2032) & (K Dose)
Figure 42. Global iPSC-Derived Natural Killer Cells Price (2021-2032) & (US$/Dose)
Figure 43. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Manufacturer in 2025
Figure 44. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Manufacturer in 2025
Figure 45. Producer Shipments of iPSC-Derived Natural Killer Cells by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 46. Top 3 iPSC-Derived Natural Killer Cells Manufacturer (Revenue) Market Share in 2025
Figure 47. Top 6 iPSC-Derived Natural Killer Cells Manufacturer (Revenue) Market Share in 2025
Figure 48. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Region (2021-2032)
Figure 49. Global iPSC-Derived Natural Killer Cells Consumption Value Market Share by Region (2021-2032)
Figure 50. North America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 52. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 53. South America iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 54. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 55. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 56. Global iPSC-Derived Natural Killer Cells Consumption Value Market Share by Type (2021-2032)
Figure 57. Global iPSC-Derived Natural Killer Cells Average Price by Type (2021-2032) & (US$/Dose)
Figure 58. Global iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 59. Global iPSC-Derived Natural Killer Cells Revenue Market Share by Application (2021-2032)
Figure 60. Global iPSC-Derived Natural Killer Cells Average Price by Application (2021-2032) & (US$/Dose)
Figure 61. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 62. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 63. North America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 64. North America iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 65. United States iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 66. Canada iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 67. Mexico iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 68. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 69. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 70. Europe iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 71. Europe iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 72. Germany iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 73. France iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 74. United Kingdom iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 75. Russia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 76. Italy iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 77. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 78. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 79. Asia-Pacific iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Region (2021-2032)
Figure 80. Asia-Pacific iPSC-Derived Natural Killer Cells Consumption Value Market Share by Region (2021-2032)
Figure 81. China iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 82. Japan iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 83. South Korea iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 84. India iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 85. Southeast Asia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 86. Australia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 87. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 88. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 89. South America iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 90. South America iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 91. Brazil iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 92. Argentina iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 93. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Type (2021-2032)
Figure 94. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Application (2021-2032)
Figure 95. Middle East & Africa iPSC-Derived Natural Killer Cells Sales Quantity Market Share by Country (2021-2032)
Figure 96. Middle East & Africa iPSC-Derived Natural Killer Cells Consumption Value Market Share by Country (2021-2032)
Figure 97. Turkey iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 98. Egypt iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 99. Saudi Arabia iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 100. South Africa iPSC-Derived Natural Killer Cells Consumption Value (2021-2032) & (USD Million)
Figure 101. iPSC-Derived Natural Killer Cells Market Drivers
Figure 102. iPSC-Derived Natural Killer Cells Market Restraints
Figure 103. iPSC-Derived Natural Killer Cells Market Trends
Figure 104. Porters Five Forces Analysis
Figure 105. Manufacturing Cost Structure Analysis of iPSC-Derived Natural Killer Cells in 2025
Figure 106. Manufacturing Process Analysis of iPSC-Derived Natural Killer Cells
Figure 107. iPSC-Derived Natural Killer Cells Industrial Chain
Figure 108. Sales Channel: Direct to End-User vs Distributors
Figure 109. Direct Channel Pros & Cons
Figure 110. Indirect Channel Pros & Cons
Figure 111. Methodology
Figure 112. Research Process and Data Source
